volume in 1 s (FEV₁) reduced to 1.7 litres (46.8% of predicted) and FEV₁/forced vital capacity (FVC) ratio 55.9%. Since his RA responded favourably on adalimumab and there was not enough evidence to ascribe his respiratory complaints to this drug, it was decided to rechallenge him with adalimumab. During the third administration of adalimumab he still used prednisolone 20 mg/day and inhaled budesonide/formoterol twice daily. On the third day following adalimumab administration he developed dyspnoea, wheezing and a reduction in his PEF to 290 l/min. His PEF went back to baseline after 2 weeks.

Bennett et al. reported a patient with presumed adalimumab-induced asthma. They hypothesised that since the tumour necrosis factor (TNF) blocker adalimumab was introduced the T helper cell (Th)1 response characteristic for RA was suppressed, allowing the Th2-activated pathway to express itself as asthma. However, patients with asthma have upregulation of the TNF axis so one would expect suppression of asthmatic inflammation. Since Bennett and colleagues assumed that the pathophysiological mechanism causing adalimumab was a direct effect of the TNF blocker, they suggested a class effect and decided not to treat their patient with other TNF blockers or other adalimumab.

started 3 days after drug administration, which is not compatible with anaphylaxis. A delayed-type T-cell mediated hypersensitivity reaction would be more likely.

At present it is unclear how often adalimumab has induced asthma-like symptoms. Because the use of adalimumab is increasing, this adverse event may become more prevalent in the future. We are the first to report adalimumab-induced bronchospasm with a positive rechallenge on the agent itself and negative challenges on etanercept and infliximab. We believe it is justified to make a switch to a different TNF blocker under strict medical observation.

R Janssen, I Krikovuca, A A Kruize, L Koenderman, J-W J Lammers

1 Department of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands; 2 Department of Pulmonology, University Medical Centre Utrecht, Utrecht, The Netherlands; 3 Department of Rheumatology, University Medical Centre Utrecht, Utrecht, The Netherlands

Correspondence to: Dr R Janssen, Department of Pulmonology, St Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands; r.janssen@antonius.net

Funding: None

Competing interests: None.


REFERENCES


Is bronchodilation required routinely before diagnostic sputum induction? Evidence from studies with tuberculosis

Sputum induction (SI) by inhalation of nebulised hypertonic saline is an efficient

PostScript


and non-invasive way of obtaining samples to assess airway inflammation and diagnose pulmonary infections such as tuberculosis (TB). Data published on the safety of SI are largely derived from subjects with obstructive lung disease. Yet on this basis a Working Group of the European Respiratory Society (ERS) recommended that all patients undergoing SI should receive pre-procedure bronchodilation with monitoring throughout by either serial forced expiratory volume in 1 s or peak expiratory flow rate (PEFR) measurements. Subjects with other respiratory conditions may not be at the same risk of bronchoconstriction as the original reference group. If so, then the recommended steps could be removed from routine SI, leading to a simplified procedure with no compromise in patient safety. Here we report our findings from routine clinical practice.

We prospectively observed 100 consecutive and unselected adult subjects undergoing SI to investigate possible TB. SI was performed using 5% hypertonic saline delivered via an ultrasonic nebuliser (Sunrise Medical, Wollaston, UK). To ensure good infection control, bronchoscopy was assessed with disposable Mini-Wright peak flow meters (Clement Clarke International, Harlow, UK). PEFR was measured at baseline and then at 5, 10, 15 and 20 min. The preselected criteria for discontinuing SI were: (1) a fall in PEFR of >15% at any time point, (2) patient choice, and (3) if the patient were deemed by the clinician performing the test to be unable to continue. Bronchodilators and resuscitation equipment were available if required. Equipment costs for generic salbutamol metered dose inhaler devices and the PEFR meter were calculated from the British National Formulary (March 2007) and manufacturer’s data.

Median age of the 100 subjects was 43 years (range 18–68) and 60 were male. Six were ex-smokers and 26 were current smokers. Median baseline PEFR was 450 l/min (range 220–710). No subject had to stop the procedure because of respiratory symptoms or a fall in PEFR of >15% from baseline. The median change in PEFR was −6.6% (range −14% to +29%) with 76 subjects having a fall in PEFR, eight no change and 16 an increase in PEFR at 20 min. None of the patients required a bronchodilator post-procedure or developed symptoms thereafter. Three of 100 patients stopped at 15 min: one with headache, one because of nausea and one as they had collected an adequate sample.

Our data argue against the current ERS guidelines. We found a low rate of bronchospasm or complications following SI in our patients being investigated for TB (including current and ex-smokers). This suggests that it is safe to omit routine bronchodilation and PEFR measurements during SI in these subjects. We estimate that removing these steps produces a saving of approximately £10 in cost and 10 min in time per procedure (which usually takes 30 min without this step). We would be interested to know whether other centres have had a similar experience in their clinical practice.

A. Dunleavy, R A M Breen, MRF Perrin, M C I Lipman

Departments of Thoracic and HIV Medicine, The Royal Free Hospital, London, UK

Correspondence to: Dr A Dunleavy, Departments of Thoracic and HIV Medicine, The Royal Free Hospital, Pond St, London NW3 2QG, UK; annedunleavy@doctors.net.uk

Funding: This study was supported by a grant from The Henry Smith Charity.

Competing interests: None.


REFERENCES


Margarine: a supplement may be decisive

A recent study in Thorax described margarine intake as a risk factor for allergic diseases (Thorax 2007; 62:677–83). This association has now been replicated in about 10 studies, but without any convincing explanation. Margarine is the only food factor to date that is associated with allergic diseases without provoking any direct allergic reaction.

Margarine was invented by the French chemist Hippolyte Mège-Mouriés at the demand of emperor Napoleon IIIrd 1869 as a cheap replacement food for his troops. The initial recipe contained water, skimmed milk and suet. Its use spread rapidly as a butter substitute, with the first factory in Oss/Netherlands exporting approximately 40 000 tons of margarine to Great Britain in 1883. As a raw material, lard was used at that time as well as copra, palm or tallow oil. As sales in the mid of the last century suffered from a somewhat poor quality image, modifications have been introduced, for example, to raise the content of polyunsaturated fats by using sunflower oil. Since 1952, vitamin D₃ has also been added to margarine in West Germany. According to a new monograph on the history of vitamin D supplementation in Germany, the company Merck delivered a highly concentrated oily vitamin solution to the Margarine Union who supplemented about the half of the 230 000 tons annually produced at that time. Since then margarine has been one of the few if not the only continuously fortified food in Germany with a major brand containing ~1 IU/g D₃.

Given more recent experimental and epidemiological findings on the immunological action of vitamin D and its metabolites, it is possible that this vitamin D supplement may be responsible for the observed effect. Changing from butter to margarine indeed leads to ~30% higher 25-OH-calciferol serum level which may be in the effective range of serum levels linked to allergic rhinitis in the NHanES study. Possibly a trial on the Crete island could answer the question of whether or not there is any causal relationship between a margarine ingredient and allergy. Vitamin D supplements could be banned from margarine for a limited time as on a sunny island there is no major fear of vitamin D deficiency in the population. Will the allergy risk remain?

M Wjst

Correspondence to: Dr M Wjst, GSF-Forschungszentrum für Umwelt und Gesundheit, Ingolstädter Landstrasse 1, Neuherberg/Munich, Germany; wjst@gsf.de

Competing interests: None.

REFERENCES


Authors’ reply

We read with great interest the letter by Wjst proposing an alternative hypothesis for margarine supplementation by vitamin D as the risk factor underlying its positive associations with asthma and allergies. In our recently published study (Thorax 2007; 62:677–83), we found that margarine intake was a risk factor for asthma and rhinitis symptoms among children in Crete. We hypothesised that the high concentration of n-6 PUFAs in margarine could partially explain the observed associations through modulation of the synthesis of IgE and inflammatory mediators.

The evidence regarding the effects of vitamin D on the development of asthma and allergies is controversial. Vitamin D has been shown to inhibit Th1 immune responses but its effects on Th2 responses are more complex and not fully elucidated. Moreover, genetic studies have provided early, although not clear, evidence of the
Is bronchodilation required routinely before diagnostic sputum induction? Evidence from studies with tuberculosis

A Dunleavy, R A M Breen, F Perrin and M C I Lipman

*Thorax* 2008 63: 473-474
doi: 10.1136/thx.2007.091439

Updated information and services can be found at:
http://thorax.bmj.com/content/63/5/473.2

**References**

This article cites 3 articles, 2 of which you can access for free at:
http://thorax.bmj.com/content/63/5/473.2#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/